Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with Recursion (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working together to advance biomarker-driven therapeutic development with a data-first approach. 

Through this collaboration, Recursion has access to Tempus’ library of de-identified, multimodal data to derive insights that have the potential to further Recursion’s therapeutic development. Recursion joins the ranks of leading biopharma companies that are tapping Tempus’ multi-modal data library and AI-enabled precision medicine solutions to accelerate and enhance therapeutic research and development efforts. As part of the agreement, Recursion will make annual payments to Tempus up to $160M in aggregate over the next 5 years.

“We share Recursion’s commitment to a data-first approach to precision medicine,” said Eric Lefkofsky, Founder and CEO of Tempus. “We look forward to working in tandem to leverage our multi-modal data to uncover insights that have the potential to advance personalized therapeutics for patients around the world.”

“We’re thrilled to announce our collaboration with Tempus,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “Combining the 20 petabytes of patient-centric oncology data we are licensing from Tempus’ library, with our multimodal biological and chemical dataset, we hope to unlock new insights that allow us to increase the speed, precision, and scale in the development of oncology therapeutics as we continue to lead the transformation from BioTech to TechBio.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.